#Boehringer Ingelheim #Brainomix #e-Lung

Brainomix e-Lung AI Imaging Technology in Clinical Trials

Brainomix, a frontrunner in AI-driven imaging solutions, has recently made significant strides by being selected by Boehringer Ingelheim for a pivotal Phase 3 clinical trial focused on pulmonary fibrosis. This milestone confirms the utility of AI technology in critical medical assessments, particularly in the realm of interstitial lung disease (ILD).

The DROP-FPF Trial

The DROP-FPF study, officially titled a Phase 3b double-blind randomized placebo-controlled trial, aims to investigate the safety and effectiveness of nerandomilast, marketed as Jascayd®, in patients with interstitial lung abnormalities—especially those with a familial predisposition to pulmonary fibrosis. This selection marks a groundbreaking moment, as it is the first-time quantitative high-resolution CT imaging biomarkers have been employed as a co-primary endpoint in a Phase 3 trial concerning ILD.

Implications of AI Imaging

The e-Lung platform, which has received FDA clearance, drastically enhances the analysis of lung CT scans by automatically quantifying and segmenting relevant data. This is particularly crucial for patients prone to pulmonary fibrosis, as the damage caused by the disease is often irreversible. In 2025, Jascayd® received FDA approval for both idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, offering a promising treatment option for patients suffering from these aggressive forms of ILD.

The Role of AI in Early Detection

The primary aim of this trial is to determine whether early intervention with nerandomilast can slow the progression of pulmonary fibrosis signs in individuals who have a family history of the condition. Pulmonary fibrosis can compromise respiratory function for millions globally. Until now, those at heightened risk have had no approved therapies available to them until symptoms manifest—typically after severe lung damage has occurred.

Martin Beck, Senior VP at Boehringer Ingelheim, emphasized the importance of prevention, stating that